Highlights of the third international conference on immunotherapy in pediatric oncology

Claudia Brehm, Sabine Huenecke, Verena Pfirrmann, Claudia Rossig, Crystal L. Mackall, Catherine M. Bollard, Stephen Gottschalk, Paul G. Schlegel, Thomas Klingebiel, Peter Bader

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The third International Conference on Immunotherapy in Pediatric Oncology was held in Frankfurt/Main, Germany, October 1-2, 2012. Major topics of the conference included (i) cellular therapies using antigen-specific and gene-modified T cells for targeting leukemia and pediatric solid tumors; (ii) overcoming hurdles and barriers with regard to immunogenicity, immune escape, and the role of tumor microenvironment; (iii) vaccine strategies and antigen presentation; (iv) haploidentical transplantation and innate immunity; (v) the role of immune cells in allogeneic transplantation; and (vi) current antibody/immunoconjugate approaches for the treatment of pediatric malignancies. During the past decade, major advances have been made in improving the efficacy of these modalities and regulatory hurdles have been taken. Nevertheless, there is still a long way to go to fully exploit the potential of immunotherapeutic strategies to improve the cure of children and adolescents with malignancies. This and future meetings will support new collaborations and insights for further translational and clinical immunotherapy studies.

Original languageEnglish (US)
Pages (from-to)349-366
Number of pages18
JournalPediatric Hematology and Oncology
Issue number5
StatePublished - Aug 2013


  • ADCC
  • Antibody-based immunotherapy
  • CAR
  • CIK
  • Chimeric antigen receptor
  • Cytokine-induced killer cells
  • HSCT
  • Hematopoietic stem cell transplantation
  • Immunotherapy
  • Natural killer cells NK
  • Oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Highlights of the third international conference on immunotherapy in pediatric oncology'. Together they form a unique fingerprint.

Cite this